MedTrace Logo

Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants

NCT01630538 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-04-19

No results posted yet for this study

Summary

The study hypothesis is that short-term low dose cyclophosphamide therapy will be effective in resolving inflammation in patients with late phase antibody-mediated rejection refractory to current standard of care treatment.

Conditions

  • Antibody Mediated Rejection

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Peter W Nickerson, MD · University of Manitoba

  • David N Rush, MD · University of Manitoba

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2018-01-18
Completion
2018-01-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01630538 on ClinicalTrials.gov